BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (2008) 81, S2-S5
© 2008 British Institute of Radiology
doi: 10.1259/bjr/30872348
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, C
Right arrow Articles by Plummer, E R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, C
Right arrow Articles by Plummer, E R
British Journal of Radiology 81 (2008),S2-S5 ©2008 The British Institute of Radiology

Full paper

PARP inhibitors and cancer therapy — early results and potential applications

C Jones, MD, MBChB and E R Plummer, MD D Phil, BMBCh

Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle upon Tyne NE2 4HH, UK

Correspondence: E R Plummer, Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH. E-mail: ruth.plummer{at}ncl.ac.uk

Polyadenosine diphosphate-ribose polymerase (PARP) inhibitors are emerging as an exciting new class of agents for treating cancer. There is pre-clinical evidence for their use to potentiate both chemotherapeutic agents and radiotherapy, and also as single agents. This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2008 by the British Institute of Radiology.